Overview

Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
This study is an open label extension of a previously completed double-blind, randomized study comparing etanercept and methotrexate in subjects with active rheumatoid arthritis. All subjects will receive combination treatment with etanercept and methotrexate.
Phase:
Phase 4
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Etanercept
Methotrexate